XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:        
Total revenues $ 7,042 $ 7,421 $ 19,892 $ 20,061
Costs and expenses:        
Cost of goods sold 1,395 1,223 4,261 3,974
Research and development expenses 1,149 1,101 3,429 3,243
Acquired in-process research and development expenses 448 65 786 270
In-process research and development impairment 0 0 2,700 0
Selling, general and administrative expenses 1,213 1,190 3,653 3,596
Total costs and expenses 4,205 3,579 14,829 11,083
Income from operations 2,837 3,842 5,063 8,978
Interest expense (229) (250) (709) (763)
Other income (expense), net (176) (154) (571) (696)
Income before income taxes 2,432 3,438 3,783 7,519
Income tax expense (646) (852) (850) (1,694)
Net income 1,786 2,586 2,933 5,825
Net loss attributable to noncontrolling interest 3 6 19 18
Net income attributable to Gilead $ 1,789 $ 2,592 $ 2,952 $ 5,843
Net income per share attributable to Gilead common stockholders - basic (in dollars per share) $ 1.43 $ 2.06 $ 2.35 $ 4.65
Shares used in per share calculation - basic (in shares) 1,255 1,256 1,255 1,256
Net income per share attributable to Gilead common stockholders - diluted (in dollars per share) $ 1.42 $ 2.05 $ 2.34 $ 4.63
Shares used in per share calculation - diluted (in shares) 1,261 1,262 1,261 1,262
Product sales        
Revenues:        
Total revenues $ 6,978 $ 7,356 $ 19,650 $ 19,848
Royalty, contract and other revenues        
Revenues:        
Total revenues $ 64 $ 65 $ 242 $ 213